| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
–Appointment brings leadership experience building and financing biopharma companies |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold |
| 20 Oct 2026 |
8-K: Other Events
On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification ... |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis C... |
| 18 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-relat... |
| 15 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-relate... |
| 28 Apr 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate... |
| 10 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
An annual meeting of stockholders of Filana Therapeutics, Inc. (the “Company”) shall be held for the election of directors at such date and time, as may be designated by resolution of the Board of Directors from time to time. Any other p... |
| 19 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders ... |
| 23 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. These actions were filed in the U.S. District Cour... |
| 18 Dec 2025 |
8-K: Other Events
Following previously reported communications with the U.S. Food and Drug Administration (“FDA”) regarding Cassava Sciences, Inc.’s (“Cassava” or the “Company”) investigational new drug application (IND) and proposed proof-of-concept clin... |
| 17 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 03 Dec 2025 |
8-K: Other Events
As previously reported, Cassava Sciences, Inc. (the “Company”) has submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) in support of a proposed proof-of-concept clinical trial for si... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorder... |
| 24 Oct 2025 |
8-K: Other Events
On October 23, 2025, the United States District Court for the District of Maryland granted the United States’ unopposed motion to dismiss with prejudice the criminal indictment against Hoau-Yan Wang, PhD. Dr. Wang is a former scientific ... |
| 22 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
AUSTIN, TX, October 22, 2025 (GLOBENEWSWIRE) – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders su... |
| 08 Sep 2025 |
8-K: Regulation FD Disclosure
A copy of the Cassava Sciences, Inc. corporate presentation, which is posted in the “Investors” section of the Company’s website at www.CassavaSciences.com, is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by refe... |
Loading...